Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of the Crohn's disease digestive damage score, the Lémann score.
Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Pariente B, et al. Among authors: reinisch w. Inflamm Bowel Dis. 2011 Jun;17(6):1415-22. doi: 10.1002/ibd.21506. Epub 2010 Nov 28. Inflamm Bowel Dis. 2011. PMID: 21560202 Free PMC article.
Infliximab: lack of efficacy on perforating complications in Crohn's disease.
Miehsler W, Reinisch W, Kazemi-Shirazi L, Dejaco C, Novacek G, Ferenci P, Herbst F, Karner J, Téleky B, Schober E, Vogelsang H. Miehsler W, et al. Among authors: reinisch w. Inflamm Bowel Dis. 2004 Jan;10(1):36-40. doi: 10.1097/00054725-200401000-00006. Inflamm Bowel Dis. 2004. PMID: 15058525
Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Rutgeerts P, et al. Among authors: reinisch w. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516. N Engl J Med. 2005. PMID: 16339095 Free article. Clinical Trial.
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. Reinisch W, et al. Gut. 2006 Aug;55(8):1138-44. doi: 10.1136/gut.2005.079434. Epub 2006 Feb 21. Gut. 2006. PMID: 16492717 Free PMC article. Clinical Trial.
A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H. Reinisch W, et al. Am J Gastroenterol. 2008 Sep;103(9):2284-92. doi: 10.1111/j.1572-0241.2008.02024.x. Epub 2008 Jul 30. Am J Gastroenterol. 2008. PMID: 18671816 Clinical Trial.
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.
Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group. Abreu MT, et al. Among authors: reinisch w. Inflamm Bowel Dis. 2009 Jun;15(6):829-36. doi: 10.1002/ibd.20833. Inflamm Bowel Dis. 2009. PMID: 19130617 Clinical Trial.
440 results